



**SENTARA HEALTH PLANS CLINICAL PRACTICE GUIDELINE:  
CONGESTIVE HEART FAILURE IN ADULTS**

For complete Guideline, please go to: 2022 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America <https://www.ahajournals.org/doi/10.1161/CIR.000000000000509>. Formularies/Drug List please visit <https://www.sentarahealthplans.com/providers/pharmacy/formularies-and-drug-lists>.

**Guideline History**

Date Approved	02/98, 07/10
Date Revised	01/00, 11/01, 03/02, 05/03 , 01/04, 11/05,01/06,05/08 , 05/10, 5/12, 11/13, 11/15, 11/17, 11/19 , 11/21
Date Reviewed	11/23
Next Review Date	11/25

These Guidelines are promulgated by Sentara Health as recommendations for the clinical Management of specific conditions. Clinical data in a particular case may necessitate or permit deviation from these Guidelines. The Sentara Health Guidelines are institutionally endorsed recommendations and are not intended as a substitute for clinical judgment.



## Heart Failure with Preserved Ejection Fraction.

The SGLT-2 inhibitor empagliflozin, sacubitril/valsartan, and spironolactone have been demonstrated to be effective in subsets of patients with HFpEF. Attention to renal function, and avoidance of use in patients with eGFR <30 is guideline based for empagliflozin and spironolactone. Sacubitril/valsartan can be prescribed when the eGFR is <30 at ½ the usual recommended starting dose. Cardiology consultation should be considered.

Charles F. Lovell, Jr., MD, FACP  
November 15, 2021